Prostate-specific membrane antigen (PSMA) targeted positron-emission-tomography (PET)/computed tomography (CT) is increasingly used for prostate cancer (PCa) staging and localization of recurrent and/or advanced disease (1). This evidence concerns the gene FOLH1 and prostate carcinoma.